BioCryst: Difference between revisions

From Bhamwiki
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:BioCryst logo.png|right|230px]]
[[Image:BioCryst logo.png|right|230px]]
'''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical research company founded in [[1986]] in [[Birmingham]] as a spin-off of [[UAB]] research. It went public in [[1994]] and moved its headquarters to Raleigh, North Carolina in [[2010]]. It maintains a 35,000 square-foot "Discovery Research Center and Laboratory Center of Excellence" with approximately 60 employees in Birmingham. The center is headed by chief discovery officer [[Yarlagadda Babu]].
'''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical research company founded in [[1986]] in [[Birmingham]] as a spin-off of [[UAB]] research conducted by [[Charles Bugg]] and [[John Montgomery]]. [[William Spencer III]], who had been involved in the launch of [[Molecular Engineering Associates]], helped the company raise start-up investments.
 
BioCryst went public in [[1994]] and moved its headquarters to Raleigh, North Carolina in [[2010]]. It maintains a 35,000 square-foot "Discovery Research Center and Laboratory Center of Excellence" with approximately 60 employees in Birmingham. The center is headed by chief discovery officer [[Yarlagadda Babu]].


Formerly headquartered at 2190 [[Parkway Lake Drive]], BioCryst develops and manufactures various types of prescription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
Formerly headquartered at 2190 [[Parkway Lake Drive]], BioCryst develops and manufactures various types of prescription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.

Revision as of 16:56, 7 July 2021

BioCryst logo.png

BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) is a pharmaceutical research company founded in 1986 in Birmingham as a spin-off of UAB research conducted by Charles Bugg and John Montgomery. William Spencer III, who had been involved in the launch of Molecular Engineering Associates, helped the company raise start-up investments.

BioCryst went public in 1994 and moved its headquarters to Raleigh, North Carolina in 2010. It maintains a 35,000 square-foot "Discovery Research Center and Laboratory Center of Excellence" with approximately 60 employees in Birmingham. The center is headed by chief discovery officer Yarlagadda Babu.

Formerly headquartered at 2190 Parkway Lake Drive, BioCryst develops and manufactures various types of prescription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.

BioCryst merged with Idera Pharmaceuticals of Exton, Pennsylvania in 2018.

Chief executives

Products

BioCryst has developed several drug treatments:

  • Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
  • Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
  • Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
  • Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
  • BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
  • Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
  • BCX-4208 Oral, for treatment of Hepatitis C
  • Orladeyo, for prevention of recurrent hereditary angioedema attacks (approved by FDA and European Medicines Agency)

References

External links

Retrieved from "http://bhamwiki.com/w/index.php?title=BioCryst&oldid=181769"